NURIX THERAPEUTICS INC's ticker is NRIX and the CUSIP is 67080M103. A total of 120 filers reported holding NURIX THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $752,288 | -21.3% | 95,711 | 0.0% | 0.04% | -27.1% |
| Q2 2023 | $956,153 | +12.5% | 95,711 | 0.0% | 0.05% | +17.1% |
| Q1 2023 | $849,914 | -19.1% | 95,711 | 0.0% | 0.04% | -34.9% |
| Q4 2022 | $1,050,907 | -15.7% | 95,711 | 0.0% | 0.06% | -25.0% |
| Q3 2022 | $1,247,000 | -0.2% | 95,711 | -3.0% | 0.08% | +10.5% |
| Q2 2022 | $1,250,000 | -9.6% | 98,687 | 0.0% | 0.08% | +11.8% |
| Q1 2022 | $1,383,000 | -51.6% | 98,687 | 0.0% | 0.07% | -36.4% |
| Q4 2021 | $2,857,000 | -0.4% | 98,687 | +3.1% | 0.11% | -16.4% |
| Q3 2021 | $2,868,000 | -40.1% | 95,711 | -47.0% | 0.13% | -46.4% |
| Q2 2021 | $4,788,000 | +359.9% | 180,480 | +439.0% | 0.24% | +397.9% |
| Q1 2021 | $1,041,000 | – | 33,486 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC | 1,822,883 | $14,327,860 | 1.60% |
| DAFNA Capital Management LLC | 556,695 | $4,375,623 | 1.36% |
| Redmile Group, LLC | 2,848,827 | $22,391,780 | 1.06% |
| Deep Track Capital, LP | 2,997,830 | $23,562,944 | 0.91% |
| WestHill Financial Advisors, Inc. | 283,333 | $2,226,997 | 0.65% |
| Soleus Capital Management, L.P. | 814,000 | $6,398,040 | 0.59% |
| Affinity Asset Advisors, LLC | 250,000 | $1,965,000 | 0.55% |
| Boxer Capital, LLC | 1,224,892 | $9,627,651 | 0.51% |
| AtonRa Partners | 24,227 | $190,424 | 0.40% |
| WASATCH ADVISORS LP | 3,564,616 | $28,017,882 | 0.18% |